Forbion
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
Mestag Therapeutics develops antibody treatments based on fibroblast immunology for cancer and inflammatory diseases. It is building therapies designed to direct and drive immune responses using fibroblast-immune biology.
Tropic secures £80m Series C led by Forbion and Corteva for gene-edited tropical crop varieties
Tropic develops gene-edited tropical crop varieties designed to improve disease resistance, shelf life and agricultural productivity. Its products aim to help growers, exporters and food supply chains manage crop disease, reduce waste and increase yields.
PACT secures £15m Series A led by Forbion and HV Capital to scale sustainable collagen-based material
PACT develops collagen-based biomaterials that replace plastic-coated textiles, supplying scalable, supple materials for fashion, interiors and automotive applications using surplus biological inputs.
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug
CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.
Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies
Verdiva Bio develops next-generation obesity and metabolic disease therapies, advancing oral and injectable treatment candidates to improve access, adherence and long-term outcomes.
More venture news
- 17 Sept 2026
MagenticMagentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers
Series ASupply Chain - 15 Sept 2026
Jack & JillJack & Jill unlocks £30m Series A led by Air Street Capital to run dual-agents on both sides of hiring market
Series AHR - 26 Aug 2026
Certain EnergyCertain Energy raises a £10m Series A led by British Business Bank for long-duration battery storage on the clean energy grid
Series AEnergy
